The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical ...
Company’s expenses for the quarter in review increased 19% to ₹279.3 Cr from ₹234.7 Cr in March quarter of FY25 IndiaMART's operating revenue increased 13.8% YoY and 0.7% QoQ to ₹404.3 Cr in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results